PROSPR Teaming Profiles
Thank you for showing an interest in ARPA-H’s Proactive Solutions for PROlonging Resilience (PROSPR) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the portal linked below. Your details will then be added to the list below, which is publicly available.
PROSPR anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the PROSPR solicitation.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Interested in learning more about the PROSPR program?
- Read the PROSPR Special Notice.
- Register to attend the hybrid Proposers’ Day.
- View the program overview page.
PROSPR Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Contact | Organization Name | Location | Description of Research Focus Area | Description of Teaming Partner | Technical Areas | |
| Alexandra Stolzing | Loughborough University | A.Stolzing@lboro.ac.uk | Loughborough | Our team works on a biomarker of aging that can predict biological age using volatiles collected non-invasively in breath. This is currently tested in a study where we observe falls. In addition, we work on improving the accuracy of the measurement and are using machine learning to automate the analysis of the metabolomic data generated. The device to collect breath is easily portable and can be operated by anyone after a short training. | We are interested in teams that want to test an intervention. We would like to run our breath biomarker of aging alongside to the study validate it. | TA3: Second generation interventions |
| John Sedivy | Brown University | john_sedivy@brown.edu | Providence, RI | Brown University Center on the Biology of Aging focuses on the molecular mechanisms of aging using a variety of model systems. We have programs in the areas of cellular senescence, epigenetics, chromatin architecture, rejuvenation, metabolism, and the microbiome. Of particular relevance to this call is our program on the activation of retrotransposable elements as a novel molecular mechanism of aging. | Clinical partners for conducting clinical trials, in particular, the repurposing of FDA approved reverse transcriptase inhibitor drugs. | TA3: Second generation interventions |
| Don Tucker | Brain Electrophysiology Laboratory Company | don.tucker@bel.company | Eugene, OR | We have developed a closed-loop EEG assessment of sleep coupled with transcranial electrical stimulation (TES) treatment to enhance deep (stage N3) sleep. The result is to improve secretion of metabolic toxins in deep sleep, and thus avoid the build up that leads to Alzheimer's Disease and Parkinson's Disease. | We are particularly interested in collaborators who can assess metabolite toxins, including amyloid beta, tau, and alpha synuclein, in a home collection protocol, for frequent assays of the improved glymphatic clearance expected by our therapeutic. | TA1: PROSPR intrinsic capacity score |
| Alexandra Blee | UCSD | majithialab@health.ucsd.edu | San Diego, CA | The Majithia lab applies the tools of functional genomics, bioinformatics, and human genetics to develop new ways to identify and treat people with insulin resistance, metabolic and age-related disease. We have extensive experience accessing and manipulating longitudinal patient datasets to identify novel biomarkers and derive insights specific to patient subpopulations. | Our lab is seeking scientific collaborators with complementary expertise including but not limited to AI experts and those with access to omics platforms. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Marla Beauchamp | McMaster University | beaucm1@mcmaster.ca | Hamilton, Ontario, Canada | Our research focus is on mobility and aging and using wearable technology to understand the relationships between digital mobility markers and measures of healthy aging in large cohort studies. We are also focused on lifestyle interventions for promoting healthy aging that leverage the use of technology. | We are looking for partners who have expertise in developing advanced wearable technologies. | TA1: PROSPR intrinsic capacity score |
| ignacio sanabria | tangled synapses | laserword@hotmail.com | miami, FL | We focus on chronic diseases, aging and how to regenerate a broken mind and a broken body. We publish on these subjects. | We are interested in partners with strong background on cell senescense, cell regeneration, mitochondria energy, telomeres shortening, DNA repair, techniques, etc. | TA3: Second generation interventions |
| Christopher Natale | Linnaeus Therapeutics | cnatale@linnaeustx.com | Haddonfield NJ, PA | We were originally inspired by clinical observations in human health, that suggest that women have superior outcomes compared to men in numerous diseases of aging, including cancer, cardiovascular, neurological, and metabolic diseases. We and others have demonstrated that activation of the G protein-coupled estrogen receptor (GPER) mediates many of these benefits. We are advancing a novel GPER agonist, LNS8801, through a late-stage clinical trial in melanoma. | We are interested in partnering with groups who have established in vivo models for testing novel therapeutics in order to evaluate activity in diseases of aging, including but not limited cardiovascular, neurological, and metabolic diseases. In human studies, LNS8801 has proven to be safe and demonstrated benefits in cancer and metabolic health. We are also interested in partnering with diagnostic companies to monitor longitudinal health measures in the context of human clinical trials. | TA3: Second generation interventions |
| Brandon Wilson | Range Bio | brandon@range.bio | San Carlos, CA | At Range Bio, we've developed a platform that enables extremely high-throughput and cost-effective deployment of targeted protein panels. We have identified dozens of promising protein biomarkers related to aging, T2D, and many other chronic diseases. Our goal is to make proteomics clinically actionable and scalable. | We are looking to partner with groups that have (or have access to) biobanked samples collected in longitudinal cohorts for validation of our markers. | TA1: PROSPR intrinsic capacity score |
| John Haughton | Renegade Research | John@renegade-research.org | Providence, RI | Up and running decentralized research in long covid and mecfs. Exploring repurposed drugs and supplements with decentralized patient community. Up and running with multiple projects getting tried and measured. Focus on immune system, microbiome, neuromodulation | Measurement / specific clinical testing ability. Grant writing. Protocol writing. | TA1: PROSPR intrinsic capacity score |
| Matthew Holbreich | Medable | matthew.holbreich@medable.com | Boulder, CO | Our organization, Medable, is primarily focused on drastically enhancing the pace and overall quality of clinical research. Our goal is to democratize access to clinical research for all Americans by deploying disruptive technologies. Our unique AI-powered software-as-a-service (SaaS) platform is designed specifically for clinical trials. Among other features, it includes consent management, participant engagement and data collection, such as eCOA, Televisit, and sensors. | Aligned vision | TA2: Repurposing FDA-approved interventions for healthspan extension |
| John Ralston | Neursantys Inc | john.ralston@neursantys.com | Menlo Park, CA | Neursantys is focused on extending the healthspan of 70 million Americans over the age of 50 by delivering AI-enabled bioelectronic restoration of their body’s aging balance system. Our digital biomarker and non-invasive neurostimulation innovations enable assessment of each person’s unique balance impairment profile with a simple 2-minute test, followed by a 6-week corrective treatment (three 20-minute sessions per week) to activate long-lasting neuroplastic restoration of balance and mobility. | Neursantsy is looking for teaming partners with: 1. clinical and technical expertise in quantitative balance, gait, and cognitive assessments in older populations 2. clinical and technical expertise in non-invasive neurostimulation in older populations 3. technical expertise in machine learning analysis of large biomechanical data sets 4. access to study populations to expand our pilot deployments 5. medical device regulatory expertise to accelerate pivotal studies and FDA approval. | TA3: Second generation interventions |
| Kemar Green | Johns Hopkins University School of Medicine | kgreen66@jhmi.edu | Baltimore, MD | Our organization focuses on precision medicine and digital neurotherapies, leveraging wearable AR/VR systems and AI-driven solutions to address neurologic conditions. Key areas include developing digital biomarkers for vision and balance disorders, creating personalized therapies, and advancing assistive technologies for aging populations to enhance healthspan and resilience. Our interdisciplinary approach combines clinical expertise, AI, and innovative neurotechnology. | We seek partnerships with non-invasive neural-AI interface companies, AR/VR device developers, wearable tech innovators, and foundations focused on balance and vision therapy for neurologic conditions. Collaborators may include disease-specific foundations, regulatory experts (e.g., FDA), and industry leaders to support research, development, and clinical validation of novel therapies that enhance resilience and address aging-related impairments. | TA3: Second generation interventions |
| Ben Pope | MelliCell, Inc. | ben@mellicell.com | Newton, MA | MelliCell works to eliminate chronic disease using ground-breaking tissue engineering technology that can unlock the promise of fat cells as a untapped disease target and a source of therapeutic adipokines. Validated through awards and agreements with leading biopharma companies, MelliCell is rapidly advancing small molecules that decrease fat mass and reverse hallmarks of disease through a novel mechanism with target indications that include aging, obesity, oncology, and inflammation. | Extensive health data, medical records, and primary human adipose tissue from large numbers of aging individuals. | TA1: PROSPR intrinsic capacity score |
| Stephen Ekker | University of Texas at Austin | stephen.ekker@austin.utexas.edu | Austin, TX | Mitochondrial DNA editing in human cells and animal models (zebrafish); mitochondrial DNA cell and animal models; precision nuclear DNA editing | Partners with aging animal model expertise; partners looking at the mitochondrial reservoir as an essential target for PROSPR diagnostics and interventions | TA1: PROSPR intrinsic capacity score |
| Thomas Seoh | Kinexum | thomasseoh@kinexum.com | Harpers Ferry, WV | Kinexum is a regulatory, clinical, non-clinical and CMC development strategic advisory firm that routinely represents clients before FDA, including cardiometabolic and healthspan "Long Bio" companies. Our thought leader reputation comes from our not-for-profit Kitalys Institute, which has organized healthy longevity conferences since 2017 and serves as a policy think tank in accelerating translation of science into public health to prevent chronic diseases and extend healthy longevity. | Winning FDA validation for Intrinsic Capacity as a surrogate marker, and IND authorization to advance agents into clinic, are essential capabilities of winning teams. Kinexum is one of the most experienced firms in engaging with FDA on extending healthspan, including advising on the composite basket endpoints for the TAME trial, on regulatory matters in connection with XPRIZE Healthspan, and various Long Bio companies on translation from pre-clinical to clinical. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Michael Snyder | Stanford School of Medicine | mpsnyder@stanford.edu | Stanford, CA | We perform longitudinal deep profiling of individuals for health and longevity studies. This includes omics, and wearables (smartwatches, CGM). We also have pioneered remote monitoring with wearables, microsampling and questionaires. | Others with complementary experience | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Sonia Grego | Coprata | sonia@coprata.com | Durham, NC, NC | Coprata‘s mission is to improve health through excreta health data measured by our Smart Toilet. Coprata has developed a hardware solution to address the barrier to specimen collection of stool, by creating the first-of-its-kind Sampling Toilet that collects specimens automatically post-flush with complete absence of physical or visual interaction. The Sampling Toilet is easy to install in the home and easy to operate for long-term biospecimen collection with limited attrition. | Our hardware solution provides unprecedented access to stool, a non-invasive specimen reflecting gut health, as well as the ability to integrate passive urine collection. We are seeking partners with assay solutions for excreta that could be fully automated and implemented in real-time in our system. We are developing a sample-to-result at-home health monitoring solution seamlessly integrated with the routine use of the bathroom and generate data to predict and prevent chronic disease. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Carlos Aguilar | University of Michigan | caguilar@umich.edu | Ann Arbor, MI | Understanding and treating skeletal muscle over lifespan using integrative genomic analysis and targeted interventions towards specific cell types. | We are interested in teaming with others on next generation therapeutics and identification of actionable targets. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Jungwoo Lee | University of Massachusetts-Amherst | jungwoo@umass.edu | Amherst, MA | We develop bioengineered human bone and marrow models for scalable, predictive preclinical drug screening to preserve tissue functions, eliminate senescent cells, and identify toxic chemicals accelerating tissue degeneration. Reducing aging-related senescent cell accumulation is crucial for health and functional longevity. We aim to achieve this by repurposing FDA-approved drugs and exploring new dietary compounds, such as flavonoids, to promote healthier aging and tissue resilience. | We seek collaborators with shared interests in pharmacological or dietary prevention of chronic disease development through diverse approaches, including animal models or clinical studies. Additionally, we are interested in partnerships focused on identifying bone and marrow-related pharmacological or dietary compounds. Our bioengineered models enhance preclinical efficacy studies and expand screening applications, fostering innovation and advancing research in these areas. | TA3: Second generation interventions |
| Daryl Waggott | Svexa | daryl@svexa.com | Svexa US HQ (Menlo Park, CA); Svexa Sweden; Svexa Poland; Zone7 Israel, CA | Our research focus is physiological algorithms leveraging data from digital and molecular biomarkers. We use these algorithms to create hyper-personalized digital twins to improve human performance, fitness, and health. Our vision is to be able to provide the optimal recommendations for everyone in any situation. We currently apply our digital twin technology to multiple verticals including sports, health insurance, women's health, and longevity. | We are a B2B SaaS company providing the backend "intelligence layer" for health and performance. Therefore we are looking for partners that have existing communities or use cases that we can support and co-develop. Our founders have academic appointments at Stanford Medicine and the Karolinska Institute and therefore can conduct research programs. For example, we are currently running a trial looking at the Physical Activity Paradox in Blue Collar workers. | TA3: Second generation interventions |
| Tatyana Dobreva | ImYoo | tatyana@imyoo.health | San Francisco, CA | ImYoo is chronicling how the human immune system changes within individuals over time and in response to acute events by working directly with patient scientists all over the US to self-collect blood samples from home. ImYoo produces research-grade biobanked PBMCs and plasma from self-collected small volume blood samples shipped to our lab, and performs downstream single-cell and other -omics assays to build a foundational longitudinal human immune atlas for age-related and chronic diseases. | ImYoo is looking for partners who 1) have study cohorts they're looking to get longitudinal samples for, 2) have computational methods they want to test with longitudinal multiomic data, and/or 3) are developing health interventions that can leverage ImYoo's existing data, biobank, or data generation capabilities. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Yun-Ling Zheng | Georgetown University | yz37@georgetown.edu | Washington, DC | Team in Zhenglab is dedicated to improving human healthspan by developing innovative, affordable telomere profiling tests for health assessment, diagnostics, and research. The ultimate goal is to offer personalized risk assessments for aging-related diseases and develop preventive strategies to reduce the burden of such diseases. | We are looking for teams that target aging-related disease intervention or diagnosis: e.g., diabetes mellitus (Type I and II), cardiovascular diseases, dementia, hematological cancers, idiopathic pulmonary fibrosis (IPF), liver cirrhosis, chronic obstructive pulmonary disease (COPD), aplastic anemia and bone marrow failure, telomere biology disorders (TBD) and premature aging syndromes. | TA3: Second generation interventions |
| Omar Costilla Reyes | Equ Healthcare | omar@equ.care | Boston, MA | Equ Healthcare focuses on developing transparent neuro-symbolic AI solutions to address health disparities in the Hispanic/Latino community. Our research includes interpretable AI for clinical decisions, culturally tailored health education, equitable mental health access, and integration of socioeconomic and linguistic factors. We aim to build trust, improve outcomes, and bridge cultural gaps in healthcare through innovative, ethical AI technologies. | Equ Healthcare seeks partners passionate about advancing health equity and innovation. We value collaboration with healthcare providers, researchers, and technologists to refine and implement AI solutions; investors to scale our impact; and community organizations to ensure cultural relevance. Ideal partners share our commitment to transparency, inclusivity, and improving healthcare outcomes for underserved populations, particularly the Hispanic/Latino community. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Elena Volpi | UT Health San Antonio | volpi@uthscsa.edu | San Antonio, TX | Translational geroscience; drug development, repurposing and testing for healthspan and longevity in animal models (rodents, non-human primates) and humans; clinical trials in older adults | Collaborators for preclinical and clinical interventions testing | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Simon Evans | Phenome Health | simon.evans@phenomehealth.org | Seattle, WA | Phenome Health is a 501(c)(3) focused on generating the data, computational tools and knowledge insights to advance data-driven health strategies. | Phenome Health focuses on human multiomic data generation and analysis and seeks partnerships for cohort access, clinical delivery of actionable insights, and commercialization paths. | TA3: Second generation interventions |
| Sameer Sonkusale | Tufts University | sameer@ece.tufts.edu | Boston, MA | * Developing wearables and point of care devices for monitoring health, mobility and cognition * Developing long term transdermal drug delivery platforms | * FDA Approved interventions * Second generation interventions * Validation | TA3: Second generation interventions |
| Ronjon Nag | R42 Group | ronjon@r42group.com | Palo Alto, CA | Drug repurposing for aging using AI | Clinical trial partners | TA3: Second generation interventions |
| Eric Verdin | Buck Institute | lnewman@buckinstitute.org | Novato, CA | The Buck Institute is the world’s first biomedical research institution devoted solely to research on aging. Everything we do revolves around our commitment to helping people live better longer. Our mission is to end the threat of age-related disease for this and future generations. We believe it is possible for people to enjoy their lives at 95 as much as they do at 25, and to achieve that, we’re seeking a more comprehensive understanding of the biology of aging itself. | e value a collaborative spirit, complementary expertise, and a focus on healthspan, longevity, and transformative impact. Ideal partners are committed to long-term, ethical, and transparent practices, bringing innovation and dedication to advancing the understanding of aging. Together, we can accelerate breakthroughs to improve healthspan and quality of life for future generations. | TA1: PROSPR intrinsic capacity score |
| Sriraam Natarajan | University of Texas at Dallas | Sriraam.Natarajan@utdallas.edu | Dallas, TX | Probabilistic Models based interventions for healthcare, multimodal analysis of long-term health, developing health scores for neurological complications and adverse pregnancy outcomes | Healthcare experts for AI-driven interventions | TA3: Second generation interventions |
| Howard Sesso | Brigham and Women's Hospital | hsesso@bwh.harvard.edu | Boston, MA | Aging, biomarkers and multi-omics, lifestyle and pharmacologic interventions, design and conduct of small- and large-scale randomized clinical trials | Technology and commercialization, laboratories, measurements | TA3: Second generation interventions |
| Ryan Smith | TruDiagnostic | ryan@trudiagnostic.com | Lexington, KY | TruDiagnostic | We have an expertise in aging biomarker algorithm creation, longitudinal interventional trials in aging, and have access to large healthy cohorts. We would be looking for individuals with remote clinical trial expertise and access to diverse populations. | TA1: PROSPR intrinsic capacity score |
| Tyona Pike | F&I Foresight Initiatives | Pikesforesightinitiatives@gmail.com | Cookeville, TN | Our focus includes supporting patients, caregivers, families, and medical teams by addressing unmet needs, enhancing awareness, and fostering partnerships to advance diagnosis, treatment, and care. We aim to work with organizations to reduce diagnostic delays, improve patient outcomes, and develop patient-centric approaches that prioritize the unique challenges posed by rare diseases | seeking a partner to handle the technical and research aspects of our efforts in the rare disease space. While we focus on growing and maintaining support for patients, caregivers, friends and family, medical teams, and those aiding individuals along the diagnostic odyssey, we aim to collaborate with an organization that can enhance our research capabilities and drive innovative solutions. Together, we can create a comprehensive support system that addresses the unique challenges faced by those | TA3: Second generation interventions |
| Jessica Lasky-Su | Brigham and Women's and Harvard Medical School | rejas@channing.harvard.edu | Boston, MA | My research group specializes in using multi-omics (e.g. DNA methylation, metabolomics, etc.) in large prospective cohorts to understand mechanisms of disease and aging. We have currently used data to generate epigenetic predictors for multiple clinical laboratories and physiologic processes that are captures in various omic data. We have assembled an initial team for PROSPR. | We are looking for partners with complimentary areas of expertise, which includes running clinical trials that we may supplement with our algorithms. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Su Guo | UCSF | Su.guo@ucsf.edu | San Francisco, CA | Aging and age-related diseases, neurological, psychiatric, | Industry partners | TA3: Second generation interventions |
| Terrie Moffitt | Duke University/Kings College London | tem11@duke.edu | Durham, NC | We developed DunedinPACE, the epigenetic speedometer that measures how fast a person is ageing and is intervention-sensitive. We track an intact pre-disease birth cohort to age 52, and have repeated clinical-quality measures of all elements to build WHO's Intrinsic Capacity model: vision, hearing, cognitive-memory, locomotive function, vitality, plus inflammation. Expertise in longitudinal approaches to precision measurement, which are essential to separate true ageing changes from artifacts. | We are building a model of Intrinsic Capacity and look for partners to convert it to novel measurement technologies to meet PROSPR's goal of implementation in healthcare. We look for partners to help extend our DunedinPACE model to new technologies. We look for partners to implement our longitudinal measures of ageing in intervention trials. | TA1: PROSPR intrinsic capacity score |
| Matthew Wheeler | Stanford University | wheelerm@stanford.edu | Palo Alto, CA | The Molecular Transducers of Physical Activity Bioinformatics Center and the MoTrPAC DataHub are building a cross-species, trans-omic, multimodal and multi-intervention dataset to create the molecular map of exercise. Our current focus is building scalable and adaptable solutions for integrative and directed analyses to identify the molecular drivers and pathways that determine the health benefits of exercise. | The MoTrPAC BIC team is interested in partnering with biotech and biopharma interested in developing diagnostics and therapeutics impacting and measuring the health benefits of exercise, and with groups with expertise in pragmatic and population interventions. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Adam Salmon | UT Health San Antonio | salmona@uthscsa.edu | San Antonio, TX | Drug development, translational geroscience, testing interventions to aging in lifespan and healthspan in rodents, NHP and humans | Basic and translational scientists, outcomes assessment and analysis, collaborators for preclinical and clinical interventions | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Dan Sexton | Omma Therapeutics | dsexton@ommatherapeutics.com | Boston, MA | Omma Therapeutics, Inc. is developing oral plasma kallikrein (PKa) inhibitors for age-related diseases, where the initial focus is diabetic macular edema. Excess plasma kallikrein kinin system (KKS) activation occurs in many diseases and during aging due to various triggers (e.g. apoptotic cells, misfolded proteins, blood microplastics, many others), to induce inflammation, thrombosis, vascular permeability, and pain. In addition, assays of KKS activation could be leveraged for TA1 | We are a small team of experienced drug developers. We would welcome the opportunity to collaborate with the assembled clinical and regulatory experts in the PROSPR team on the design of innovative clinical studies to advance our our preclinical stage inhibitors to clinical testing | TA1: PROSPR intrinsic capacity score |
| Reza Dana | Harvard Dept Ophthalmology/MEE | reza_dana@meei.harvard.edu | Boston, MA | Ophthalmology; Ocular Surgery; Vision Science Therapeutics | We are interested in 1) slowing down aging / degeneration of ocular tissues and 2) promotion of tissue regeneration | TA1: PROSPR intrinsic capacity score |
| Ishanu Chattopadhyay | University of Kentucky | ishanu_ch@uky.edu | Lexington, KY | Our zero-burden risk score (ZCoR) suite of algorithms allows for assessment of current and future risks for complex disorders with minimal or zero burden on patient and with no new tests or bloodwork, leveraging advance AI to recognize predictive signatures in the history of medical encounters. Thus our tools can inform IC scores enabling passive, non-invasive monitoring of health risks. | Ability to validate and benchmark our algorithmic tools with direct patient interactions and studies in diverse settings. | TA3: Second generation interventions |
| Michael Geer | Humanity | mg@humanity.email | Boston, MA | Humanity uses new generation AI methods to create and deploy generalizable Biological Age models through our mobile app and API. The Humanity app also then guides users to slow their Biological Age by monitoring and then feeding back to users what group of actions for what type of user is working to lower Biological Age across the userbase. The focus is mainstream public health level solutions. | We are looking for partners that are looking to build out a solution that allows for all researchers, testing companies, and intervention providers to work together to create a public good that delivers on the goal of the program to make everyone healthier for longer. We have the expertise to help lead this overall process with amazing partners. | TA3: Second generation interventions |
| Thomas Peterson | UCSF | thomas.peterson@ucsf.edu | San Francisco, CA | As a member of the UCSF Bakar Institute for Computational Health Sciences, our group integrates cutting-edge AI/ML techniques to advance predictive outcome models for aging and chronic disease. We leverage multimodal data from large-scale cohorts like BACPAC, MOST, and Mr. Oz, focusing on person-specific outcome predictions. Our work emphasizes ML fairness, integrating social determinants of health and biospecimen assays to design precision medicine tools that enhance clinical decision-making. | We seek collaborators skilled in developing and deploying at-home biospecimen tests and teams with strong patient recruitment capabilities. Our extensive cohorts of deeply phenotyped musculoskeletal conditions from HEAL/BACPAC, Mr. Oz, and MOST provide a foundation along with experience in clinical trial deployment. With pre-collected data and readiness for immediate deployment, we aim to meet ambitious timelines and drive innovative research. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Chiara Herzog | King's College London | chiara.herzog@kcl.ac.uk | London, UK | My organisation works on biomarkers of aging, health and resilience across diverse omics. I have previously planned and overseen human multi-omic intervention trials and developed tests compatible with self-sampling and home testing for detection of cancer. | Technology for home testing/sampling, drug repurposing expertise | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Negin Hajizadeh | SenseMed | admin@sensemed.health | New York City, NY | SenseMed is interested in increasing longevity by using trauma-therapy based principles to reverse epigenetic changes and lifestyle choices resulting from chronic stress and trauma. These methods include distilling Acceptance and Commitment Therapy principles into usable, self-applied strategies for people to employ in their own lives, breathing techniques, nutrition and sleep optimization, somatic experiencing techniques, art therapy and contemplative practice such as meditation. | We are looking for partners that can execute home-based citizen scientist fueled clinical trials, as well as labs that can analyze epigenetic changes and mitochondrial functioning profiles. We provide the mental health expertise as well as functional medicine and allopathic medical know-how. Together with basic science and clinical trialist partners we can test the effect of targeting one of the leading root causes of deteriorating health as we age: chronic stress and T(t)rauma. | TA3: Second generation interventions |
| Tim Clark | Oura | timothy.clark@ouraring.com | Dallas, TX | Oura’s mission is to give every body a voice. We pride ourselves on industry-leading wearable device accuracy, a strong foundation in health research, and educational tools to help people live healthier lives. Oura Ring has been featured in dozens of clinical trials at well-known research institutions focused on (but not limited to) sleep, cardiovascular, and metabolic health, and we continue to collaborate with leading academic institutions on innovative Women’s Health research. | We are looking for 1) collaborators looking to deploy wearable and other human observation/sensing capabilities as part of their solution, 2) partners interested in scalable collection of daily factors that contribute to longevity (sleep health, metabolic health, stress and resilience levels), and 3) those interested in developing and deploying platform solutions that operate both within and outside of traditional health care settings. | TA3: Second generation interventions |
| Hugo Arellano-Santoyo | RA Ventures | hugo.arellano@raventures.com | Boston, MA | Development of novel Therapeutics across all therapeutic areas and some diagnostic tools | Deep mechanistic understanding of scientific pathways; enthusiastic and doer mindset and culture fit | TA3: Second generation interventions |
| Mehdi Javanmard | RIZLAB HEALTH, INC. | Javanmard@rizlabhealth.com | Princeton, NJ | Product development for point of care blood analyzers (blood cells and serum markers) | data anlaytics | TA1: PROSPR intrinsic capacity score |
| Mikko Pitkänen | Propellerhat Management Oy | Mikko.pitkanen@propellerhat.co | Helsinki | Innovation Management performance coaching for Research and development teams. | New innovations and partnerships | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Nancy Rawson | Monell Chemical Senses Center | nrawson@monell.org | Philadelphia, PA | The Monell Center is a nonprofit, independent research institute devoted to taste, smell, and nutrition. We are a world leader in sensory science with a 55+-year legacy of excellence in research and training. We work across disciplines to advance our understanding of our external and internal chemical senses to improve diets, health and quality of life. We have extensive expertise in rigorous, scalable and efficient testing of taste and smell function across the age span. | We are looking to join a team to add our expertise in smell testing to improve early detection of dementia. Smell function has been demonstrated to be a highly sensitive indicator of overall health and neural/cognitive ability. It can be done noninvasively, quickly and inexpensively using a validated test called Scentinel(tm). Adding regular smell testing to other regularly conducted screening measures could vastly improve our ability to identify people at risk of dementia earlier. | TA3: Second generation interventions |
| Gareth Hughes | Caizio | gareth.hughes@caizio.com | Dallas, TX | Biosensor design, development, and prototyping including wearables. | Expertise in measuring relevant physiological and biochemical markers. | TA1: PROSPR intrinsic capacity score |
| Yong Li | Baylor College of Medicine | yong.li@outlook.com | Houston, TX | Partial reprogramming with Yamanaka factors can extend animal lifespan, yet it may increase cancer risk. Many hallmarks of aging are antithetical to those of cancer. For example, anti-aging approaches targeting hallmarks like stem cell exhaustion could inadvertently promote oncogenesis. LINE-1 retrotransposons are activated in cancer and during aging. Targeting these retroelements may extend healthspan by addressing aging while miminizing cancer risk. | We have developed DNA-encoded vaccines, monoclonal antibodies, and small compounds powered by artificial intelligence against the ORF1p protein of the human LINE-1 retrotransposons. We are looking for partners who have model systems to evaluate the interventional therapeutics to enhance healthspan. | TA3: Second generation interventions |
| Carol Satler MD PhD | Insilico Medicine | carol@insilicomedicine.com | Cambridge, MA | Insilico Medicine with global headquarters in Cambridge, MA is a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates. | We are interested in teaming partners focused on development of new agents to address age-related diseases and longevity. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Christin Glorioso | NeuroAge Therapeutics | christin@neuroagetx.com | San Francisco, CA | NeuroAge Therapeutics is a longevity techbio startup that is reversing brain aging to prevent dementia. Based on 20 years of research at MIT and CMU, the NeuroAge Test uses AI to predict brain age and risk of dementia more than 30 years ahead of time. It has four parts 1. brain MRI 2. cognitive testing 3. blood RNA-based brain aging clock 4. polygenic risk score and allows people to track their lifestyle to improve their cognitive health. | We are looking to partner with organizations with complimentary testing and interventions for overall aging beyond the brain. | TA3: Second generation interventions |
| Chris Yoo | Yoo & Co Accelerators | chris@yooandco.com | Phoenix, AZ | Development of consortia to accelerate the translation of clinical need into rapid technology development in these areas: medical devices (WearTech, longitudinal biomarker sampling, remote patient monitoring, data acquisition, integration, analysis, Digital Twin platforms, patient-physician digital interface). | Academic medical centers, biomarker and diagnostics companies, IT infrastructure providers | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Suzanne Hendrix | Pentara | shendrix@pentara.com | Salt Lake City, UT | Development of Intrinsic Capacity scores and digital biomarker measures | Clinical sites for assessing IC score performance and for performing clinical trials | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Natalia Bk | Sustainable Healthcare Corps | we@sustainablehealthcare.life | New York, NY | Healthcare missed opportunities a-->z | Research integrity, solid foundation, collaborative spirit, security/NDA mindfullness | TA2: Repurposing FDA-approved interventions for healthspan extension |
| John Ralston | Neursantys Inc | john.ralston@neursantys.com | Menlo Park, CA | Neursantys is focused on extending the healthspan of 70 million Americans over the age of 50 by delivering AI-enabled bioelectronic restoration of their body’s aging balance system. Our digital biomarker and non-invasive neurostimulation innovations enable assessment of each person’s unique balance impairment profile with a simple 2-minute test, followed by a 6-week corrective treatment (three 20-minute sessions per week) to activate long-lasting neuroplastic restoration of balance and mobility. | Neursantsy is looking for teaming partners with: 1. clinical and technical expertise in quantitative balance, gait, and cognitive assessments in older populations 2. clinical and technical expertise in non-invasive neurostimulation in older populations 3. technical expertise in machine learning analysis of large biomechanical data sets 4. access to study populations to expand our pilot deployments 5. medical device regulatory expertise to accelerate pivotal studies and FDA approval. | TA1: PROSPR intrinsic capacity score, TA3: Second generation interventions, TA2: Repurposing FDA-approved interventions for healthspan extension |
| Gil Blander | InsideTracker | gblander@segterra.com | Cambridge, MA | InsideTracker provides a personalized health analysis and wellness guide to help members live healthier, longer lives. By analyzing blood, DNA, fitness tracker, and questionnaire data, we deliver an objective view of well-being. Our AI-powered platform uses insights from peer-reviewed research and 10B+ biomarker data points to create actionable recommendations. With over 100K users, our unique biological dataset drives groundbreaking science, all integrated into an intuitive mobile app. | We specialize in aging biomarker algorithm creation, longitudinal interventional trials, and large healthy cohorts. we seek partners to leverage our technology and data assets for intervention development and those interested in using our virtual clinical study tool. Ideal collaborators include biotech, pharma, AI, tech, research institutions, and non-profits committed to deploying blood, DNA, wearables, and questionnaire data solutions within and beyond traditional healthcare settings ethically | TA3: Second generation interventions, TA1: PROSPR intrinsic capacity score |
| Mahdi Moqri | Biomarkers of Aging Consortium | mmoqri@bwh.harvard.edu | Boston, MA | We are a consortium of scholars and practitioners developing, validating, and implementing biomarkers of aging and longevity. Our academic members are affiliated with the leading research institutes and groups in the field of aging. Our practitioners are at the forefront of research and development in the longevity industry: https://www.agingconsortium.org | We are looking for complementary expertise to cover the TA1. We have extensive expertise in cohort data harmonization with access to most of the required datasets (Biolearn Library), strong expertise in omics biomarkers development and validation, in particular in DNA methylation ($20 targeted assay) and proteomics (biomarkers trained on UK Biobank data). | TA1: PROSPR intrinsic capacity score |
| ignacio sanabria | tangled synapses | laserword@hotmail.com | Miami, FL | Sorry for The boldness. "How not to grow old and ill..." | Preventing diseases from ocurring in The first place | TA1: PROSPR intrinsic capacity score, TA3: Second generation interventions |
| Maksym Krutko | imec USA | max.krutko@imec-int.com | Boston, MA | At imec, we developed a vitamin-pill-sized gastrointestinal sampling pill with location-sensing technology for precisely triggered sampling at any point in the intestine or colon. Easy to swallow and retrieve, it offers a novel, non-invasive way to collect digesta and biomarkers. In addition, we developed a speckle sensor operating at ~1 meter, that allows for unobtrusive physiological biomarker extraction. This technology can be applied as bedside monitor or total body scan in the bathroom. | Our sampling pill provides access to biological specimens that are otherwise inaccessible, opening doors for novel research and applications. Likewise, the speckle sensor uniquely enables long-term physiology monitoring and novel biomarker extraction. We seek collaborators with expertise in identifying and analyzing aging biomarkers within digesta and the microbiota as well as cardiovascular physiology. | TA1: PROSPR intrinsic capacity score |
| Ian White | Space-Aging Research Institute (SARI) | drwhite@spaceaging.org | Gainesville, FL | At SARI we are committed to asking the right questions about aging, because only by asking the right questions can we expect the correct answers. We are reconciling the fields of biology, chemistry and physics to understand how and why humans age and what we can learn from species that age slowly or are capable of stopping and even reversing biological aging. By exploring Dr. White's theory of eA (Aging due to entropy) we are finally asking the right questions. | We're looking for capital to fund further work into our novel longevity and regenerative medicine therapeutic ViX001, which recently received FDA IND approval for phase I/II clinical trials. We're looking for committed partners who can help use develop the next generation of longevity therapeutics based on mechanisms which facilitate the effects of ViX001. | TA3: Second generation interventions |
| Lily Clayton | age1 | lily@age1.com | San Francisco, CA | Funding partner for novel TA3 interventions. age1 is a venture capital firm that backs companies targeting the biology of aging to treat, prevent, and reverse disease. Our team has been the first investor in Loyal (FDA protocol concurrence for lifespan extension in dogs), founder of Cradle Health, and investor in Gordian Bio, Fauna Bio, Arda Tx, General Proximity, and many more. | Founder-led startups and university spinouts developing therapeutics to protect intrinsic capacity and slow age-related decline. We're interested in robust in vivo functional data (e.g., frailty). | TA3: Second generation interventions |
| Solveig Sieberts | Sage Bionetworks | solly.sieberts@sagebase.org | Seattle, WA | Sage Bionetworks is a trusted leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. We specialize in data coordination and sharing of clinical, -omics and digital health data, including the ELITE portal which houses data pertaining to longevity and aging. We also specialize in crowdsourcing solutions to computational biology problems. We boast a community of 30,000 solvers who help identify optimal solutions. | Subject matter experts in the aging (IC) space, data collectors, teams looking for computational/AI expertise. | TA1: PROSPR intrinsic capacity score, TA3 |
| Bess Frost | Brown University | bess_frost@brown.edu | Providence, RI | The Center for Alzheimer's Disease Research at Brown University is designed with a single goal in mind: Find cures for Alzheimer's disease and related dementias. The Center fuels and funds research, uniting more than 100 physicians, scientists and public health experts. By fostering a culture of out of the box thinking, we focus on identifying novel therapeutic targets and pioneering drug development approaches that go beyond traditional pathways. | Partners for clinical trial development and execution | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Peter Ricci III | Trace Sensing Technologies Inc. | pricci@tracesensing.com | Wallingford, CT | Trace Sensing Technologies’ current research focus is the continued development of our medical diagnostic tool, TRACE-E. Occurring much closer to disease onset, novel breath biomarkers (VOCs, proteins, etc.) enable diagnosis at earlier stages by offering pre-clinical resolution. Achieving unprecedented sensitivity, 50,000 times greater than existing methods, TRACE-E identifies and measures biomarkers in breath at the molecular level for non-invasive disease diagnosis and monitoring. | We are looking for clinical research partners interested in using our rapid, non-invasive diagnostic tool to validate their proposed lifestyle interventions through the detection of novel breath biochemical markers of aging. | TA1: PROSPR intrinsic capacity score |
| Eva Maria Janerus | Alden Scientific | evamaria@aldenscientific.com | Boston, MA | Alden Scientific is a private research institute. We have built the world’s most sophisticated multi-omic AI and are applying it to predict, prevent, diagnose, manage, and treat many of the conditions that most affect health and well-being, today. | Longitudinal multi-omic samples. Funding. Clinical trials. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Stephen Applebaum | EM Neuroimaging | sia@emneuroimaging.com | Phoenix, AZ | MEG and EEG | organizations that need access to functional brain imaging paradigms | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Albert Higgins-Chen | Yale University | a.higginschen@yale.edu | New Haven, CT | We generate aging biomarkers tailored for clinical trials. We constructed the TranslAGE knowledgebase, which utilizes harmonized datasets and pipelines to systematically report properties of any given aging biomarker including prediction of aging outcomes, confounders, test-retest reliability, relationship to mental health, and responsiveness to 51+ interventions. Interventions include diet, exercise, supplements, senolytics, rapamycin, metformin, hyperbaric oxygen, semaglutide, gene therapy. | We seek partners who wish to leverage the TranslAGE knowledgebase to inform clinical trial design (select biomarkers responsive to their intervention, conduct power analyses, identify confounders, find existing validation datasets). The available interventions are appropriate for all tracks (TA1, TA2, TA3). TranslAGE is currently focused on DNAm data due to availability of intervention data, but we would work with other teams to construct TranslAGE knowledgebases for other biomarker types. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Peter Adams | Sanford Burnham Prebys Medical Discovery Institute | padams@sbpdiscovery.org | La Jolla, CA | Aging, healthy aging interventions in mouse models, models of mouse frailty and aging, early stage drug discovery and development. | 2nd generation interventions for early stage testing in TA3. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Jerry Colca | Cirius therapeutics | Jcolca@ciriustx.com | Kalamazy, MI | We are developing second generation insulin sensitizers that work through a recently identified mitochondrial target. Clinical studies have involved diabetes, liver disease, an Alzheimer’s. | We have a number of academic partners, but need more help getting to the optimal registration endpoints. | TA3: Second generation interventions |
| Donna Roberts | ISS National Laboratory/Center for the Advancement of Science in Space | droberts@issnationallab.org | Melbourne, FL | The International Space Station (ISS) and its unique microgravity environment enables research and technology development not possible on Earth. Spaceflight has been shown to accelerate aging and promote cancer development impacting organ systems throughout the body from the cellular to whole organism levels providing a unique opportunity to study aging in a compressed timeframe. The ISS National Laboratory provides researchers with access to the ISS. | The ISS National Laboratory provides researchers with access to the ISS. We would be glad to discuss with investigators potential partnership pathways to incorporate utilization of ISS research capabilities into their proposals in response to the ARPA-H PROSPR ISO solicitation. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Clinton Hughes | Youth Renewal Sciences LLC | clinton@youthrenewal.com | Phoenix, AZ | Organization is focus on targeting interventions/protocols to reduce/reverse the 12 hallmarks of aging. | Organization is open to collaboration with other partners. | TA3: Second generation interventions |
| Bruno Bale | Ani Biome | genius@anibiome.ai | San Francisco | Ani Biome develops AI-driven digital biomarkers and multi-agent systems for personalized health. Our research integrates multi-omics data to quantify intrinsic capacity and repurpose FDA-approved interventions for healthspan extension. By linking biological, cognitive, and affective states, we create scalable solutions for resilience and longevity. | Ani Biome seeks partners who can leverage our digital biomarker and platform to significantly lower overhead and increase data influx. Our clinically proven interventions reduce side effects, improve endpoints of existing treatments, and have the potential to turn non-responders into responders—critical for optimizing outcomes in repurposing FDA-approved interventions. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Owen Carmichael | Pennington Biomedical Research Center | owen.carmichael@pbrc.edu | Baton Rouge, LA | Pennington Biomedical Research Center focuses on enhancing metabolic health throughout the lifespan from cells to society. Our service core infrastructure provides the cutting-edge phenotyping and intervention resources that faculty utilize to explore mechanisms underlying obesity, diabetes, aging, neurodegenerative disease, and related phenomena at small animal, human, and community levels. | We provide a wealth of experience in state-of-the-art human phenotyping as well as behavioral and pharmaceutical intervention. We also have deep expertise in animal models of obesity, diabetes, and exercise. We seek team counterparts who are experts in aging biology, whose expertise will inform study design and interpretation of phenotyping data at a molecular level. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| James Banal | Cache | james@cache-dna.com | San Carlos, CA | Cache is developing breakthrough preservation technology for ambient-temperature storage of diverse biological molecules, eliminating cold-chain requirements. Their novel encapsulation approach maintains molecular integrity while enabling unprecedented scalability for longitudinal studies - a key limitation of current cold-storage paradigms. This technology could expand population-scale molecular analysis, and accelerate advances that improve health outcomes and extend healthy lifespans. | We seek partners with established clinical networks managing longitudinal aging/disease cohorts and expertise in high-throughput molecular analysis (nucleic-acid sequencing, proteomics, metabolomics). Ideal collaborators will have proven capabilities in multi-site studies, multi-omics data integration, and advanced bioinformatics. | TA1: PROSPR intrinsic capacity score |
| Justin Briggs | Azalon Therapeutics | jbriggs@zafrens.com | San Diego, CA | Azalon Therapeutics discovers and develops novel medicines targeting epigenetic regulatory proteins to control cell state, fate and function, and to treat diseases, resolve cancer and extend longevity. Azalon uses the Z-Screen uHTS platform to conduct massively parallel cell-based assays with high content imaging, functional readouts, transcriptomics and proteomics in the same assay. We are building the world’s largest dataset on epigenetic chemical perturbations and discover novel medicines. | Collaborators with capabilities, compatible assays, targets or chemical matter of interest in epigenetic modulation. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Christopher Bradley | Matter Bio | chris@matterbio.com | New York City, NY | Matter Bio is working on extending healthy longevity through optimizing genomic integrity. We draw on the information theory of aging, hypothesizing that age-related diseases stem from cumulative DNA damage. Inspired by long-lived species with superior DNA repair, we deliver protective variants to human cells. Our approach includes precision sequencing (ecNGS), repairing and replacing damaged genes, and removing harmful cells. | We'd love to partner with labs and researchers who have novel assays, in-vivo models or samples that we could collaborate one to determine DNA stability, repair, damage and longevity readouts. | TA1: PROSPR intrinsic capacity score |
| Irina Conboy | UC Berkeley | iconboy@berkeley.edu | Berkeley, CA | The Conboy lab studies plasticity of aging and develops approaches for engineering healthy longevity. | We would like to partner with clinicians who focus on aging-associated diseases. | TA1: PROSPR intrinsic capacity score |
| Tom Benson | Mitrix Bio Inc. | tom@mitrix.bio | Pleasanton, CA | MItrix Bio Inc. uses bioreactor-grown young mitochondria, transplanted into the body in large volumes, to cure age-related diseases (Alzheimer's, AMD, Parkinson's, frailty, CVD, etc.). Also next month starting human trials to attempt a 130-year human lifespan in 5 volunteers ages 65-90. We have top scientists from Stanford, Northwell Health, U Conn, and Univ Laval in Quebec. Dr. Thomas Rando (UCLA), Dr. Mike Snyder (Stanford), and Dr. Scott Parazynski (ex-NASA astronaut) as advisors. | We are seeking compatible 2nd-generation treatments (exosomes, stem cells, epigenetic reprogramming). We believe mitochondrial replacement is an excellent co-therapy with these other therapies. | TA1: PROSPR intrinsic capacity score |
| Ashkan Afshin | Novelna Inc. | ashkan@novelna.com | Palo Alto, CA | Novelna Inc. is developing first-in-class biomarker panels leveraging low-abundance proteins optimized for aging and early disease detection. | Novelna Inc. is seeking collaboration with organizations that provide expertise related to therapeutics for comprehensive healthspan enhancement. | TA1: PROSPR intrinsic capacity score |
| David Furman | Buck Institute for Research on Aging | Dfurman@buckinstitute.org | Novato, CA | The Buck Institute focuses on understanding aging mechanisms and developing interventions to enhance healthspan and lifespan. Key areas include cellular senescence, mitochondrial dysfunction, chronic inflammation and DNA repair. Research addresses neuro-degeneration, immunosenescence and age-related decline in Intrinsic Capacity. Cutting-egde work includes epigenetics, stem cell therapies, and drug discovery to combar age-related disease and extend healthspan. | The Buck Institute seeks partners to advance aging science and healthspan extension. Ideal collaborators include research institutions with expertise in neuroscience, immunology, or metabolism; biotech and pharma companies focused on age-related diseases; AI and tech experts in systems biology; clinical research organizations for translational studies; government and non-profits supporting public health goals; and strategic investors to accelerate commercialization of therapies and diagnostics. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| DAVID ALLISON | Indiana University Bloomington | Allison@IU.edu | Bloomington, IN | Design, analysis, and interpretation of healthspan and lifespan studies, especially from the perspectives of statistics, causal inference, and comparative biology. | Persons with the ability to co-design and then implement experimental (randomized) studies in humans or model organisms of other longevity and health span studies with strong causal inference approaches. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Tae Seok Moon | J. Craig Venter Institute | tsmoon7@gmail.com | La Jolla, CA | Longevity, synthetic biology, synthetic cell, health, genetic circuit, environmental engineering, climate engineering, and AI | Clinical expertise, drug screening, and animal test expertise | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Anders Naar | University of California, Berkeley | naar@berkeley.edu | Berkeley, CA | We have employed human genetics to identify a pathological microRNA, miR-128, that contributes to a range of aging-related diseases such as cardiometabolic disorders, heart failure and sarcopenia. We have developed a potent and well-tolerated antisense therapeutic that ameliorates pathological manifestations in all disease contexts in mouse models, and which exhibits an excellent safety profile in mice, pigs and NHPs. | We would like to expand our focus to testing the anti-miR-128 ASO in additional aging-related diseases, including neurodegenerative diseases, and are also interested in teaming up with scientists and clinicians who are experts in aging/healthspan-related research in animal models and in humans. | TA3: Second generation interventions |
| Javier Tordable | Pauling.AI | javier@pauling.ai | Seattle, WA | Pauling.AI is building an AI platform for insilico drug discovery. We aim to automate the process to go from an idea about a therapeutic to a molecule that can be tested in the lab, and make it much faster and efficient. | We are looking to partner with therapeutic teams who can use our technology. In particular complimentary teams with experimental expertise but no computational chemistry or AI expertise. Our technology will enable them to find novel small molecules and analogues to approved drugs much faster than competing approaches. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Martin Borch Jensen | Gordian Biotechnology | martin@gordian.bio | San Francisco, CA | Gordian is able to run in vivo efficacy tests simultaneously for hundreds of therapies up- or downregulating individual genes, through a combination of gene therapy and single cell transcriptomics. We apply this in patient-like animal models (including aged animals, spontaneous disease etiology, non-rodents) to causally validate biological hypotheses on how to treat or prevent age-related diseases, and develop effective therapies. | Experience with small molecular drug repurposing; expertise in relating circulating proteo/other -omics to physiological outcomes. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Daniel Belsky | Columbia University | db3275@cumc.columbia.edu | New York, NY | The AFAR FAST Initiative aims to accelerate development of biomarker surrogate endpoints for healthspan extension intervention trials. FAST will generate multi-omics data from successful randomized controlled trials of FDA-approved drugs with evidence of gerotherapeutic properties. Intersection of omics analysis across trials will establish drug impacts on aging biology, discover biomarkers of gerotherapeutic treatment response, and allow testing of candidate surrogate endpoint biomarkers. | FAST is led by AFAR and supported by an SAB composed of geroscience leaders from academia and industry with expertise in aging biology, proteomics, metabolomics, computational biology, bioinformatics, and statistical analysis of randomized trials. We seek partners with access to samples from completed clinical trials of SGLT-2 inhibitors, GLP-1 agonists, metformin and lifestyle intervention in the DPP trial, and bisphosphonates as well as partners who can augment the expertise of our SAB. | TA1: PROSPR intrinsic capacity score |
| Kevin Pacheco-Barrios | Spaulding Rehabilitation Hospital | Kpachecobarrios@mgh.harvard.edu | Cambridge, MA | Autonomic modulation to promote healthy aging. Use of multimodal brain assessments to evaluate brain resilience in older adults. | We are looking for partners to enhance the scalability of our new interventions and validation of its clinical profile. | TA1: PROSPR intrinsic capacity score |
| John Beard | Columbia University | Jrb2297@cumc.columbia.edu | New York City, NY | Investigators from Columbia Aging Center have led global work to conceptualize and operationalize the construct of intrinsic capacity and phenotypic trajectories of aging. We approach these as multidimensional, dynamic characteristics that change across the life course. We have access to reference cohorts and expertise to define norms for biochemical, physiological and functional metrics and to develop algorithms that integrate data into measures of capacity and its molecular signatures. | The Columbia University Aging Center team includes John Beard (who led WHO's work on intrinsic capacity), Dan Belsky, and Ying Wei, supported by interdisciplinary faculty. We seek partners for collaboration on development of cohort and intervention studies, who have expertise with development of data capture and dissemination technology, and who are interested in working with us to develop and refine measurement and communication of intrinsic capacity and its molecular signatures. | TA1: PROSPR intrinsic capacity score |
| Záda Beasley | ZataData®️ | hello@zatadata.world | Hanover, MD | ZataData's research within the ARPA-H PROSPR program focuses on leveraging AI/ML to combat age-related decline. Key areas include: Predictive Modeling: AI models to predict individual trajectories of aging. Personalized Interventions: AI-powered platforms to recommend personalized interventions. Novel Biomarker Discovery: AI to identify novel biomarkers of aging. Drug Repurposing: AI to identify existing drugs for age-related disease prevention. ZataData aims to improve the health lifespan. | An ideal ARPA-H PROSPR partner would be a leading gerontology research center. For example, the National Institute on Aging (NIA) possesses extensive expertise in aging research, access to large longitudinal datasets, and a network of collaborating researchers. This partnership would provide ZataData with invaluable resources and insights to accelerate the development of AI/ML solutions for healthy aging. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Pamela Tenaerts | Medable | pamela.tenaerts@medable.com | Palo Alto, CA | Medable offers a cloud-based SaaS platform that streamlines data collection during clinical trials. Medable connects patients, research sites, and pharmaceutical companies, ensuring patient safety and eliminating the burdens of traditional (non-digital) clinical trials. Medable's technology cuts trial time and cost, enabling approval of effective therapies and into the market faster. | academic research insitutions, Helatcare providers, and Phrama and biotech partners, | TA3: Second generation interventions |
| Lee Rubin | Harvard University | lee_rubin@Harvard.edu | Cambridge, MA | The role of blood factors in mediating interactions between brain and body. | Blood analyses from humans and animal models | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Alan Cohen | Columbia University | aac2277@cumc.columbia.edu | New York, NY | Developing dynamic, high-dimensional metrics of biological (intrinsic) health and resilience | Access to relevant data to use, collaborators with relevant modeling skills to complement ours | TA1: PROSPR intrinsic capacity score |
| David Scieszka | Vertical Longevity Pharma | dscieszka@velopharma.com | Irvine, CA | A senolytic vaccine that shows curative potential in atherosclerosis, the leading cause of mortality in the US. Additionally, we see outcomes related to prolapse prevention, pulmonary protection, hair loss reductions, and lifespan extension. | Investment partners, clinical partners, and pharma partners. We have animals ready for purchase but lack the funds to intervene therapeutically. | TA3: Second generation interventions |
| Xinru Wang | University of Washington | xinruwang7@gmail.com | Seattle, WA | Computational design of synthetic hormones | I'm excited to start my own research group this fall, focusing on longevity. I look forward to collaborating with experts in preclinical and clinical models to advance this field. | TA3: Second generation interventions |
| David Medrano | University of Texas Southwestern | david.medrano@utsouthwestern.edu | Dallas, TX | we are currently looking to increase health span by using Stem cells, enhanced mitochondria, and repurposed or reposition FDA approved drugs. | we are looking for team members second compliment our team with expertise in Stem cells and in vivo aging animal models and characterization. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Esther Rawner | Alkahest, Grifols | esther.rawner@grifols.com | San Carlos, CA | Alkahest, a Grifols company, pioneered plasma-based advanced omics research that has lead into clinical development to address aging and age-relating diseases. Out work includes cutting-edge proteomics, transcriptomics and discovery mass spec targeting neurodegeneration, frailty, and inflammaging. Grifols, a global leader in plasma-derived medicines, enhances health through innovation in transfusion, diagnostic and therapeutics. | Alkahest is seeking potential partners with expertise in translating the data from the R&D experiments and clinical trials into biomarkers. Partners would have experience in data integration, translational science and clinical trials. | TA3: Second generation interventions |
| Peter Washington | University of California, San Francisco | peter.washington@ucsf.edu | San Francisco, CA | As an assistant professor of clinical informatics at UCSF, I have expertise in AI using wearables and smartphone data. I am happy to partner with teams who could leverage this. | I am not looking to lead, but rather to join an existing effort given my expertise in AI using wearables and smartphone data. | TA1: PROSPR intrinsic capacity score |
| Paul Stewart | Tranexamic Technologies | wpstewart7@gmail.com | Dallas, TX | We are repurposing a drug that reduces chronic systemic inflammation and modulates the innate immune system and thereby promises to reduce the incidence of the many diseases associated with systemic inflammation and significantly increase healthspan. We have devised a clinical trial program with the highly regarded University of Florida Dept of Physiology and Aging that can align with the PROSPR requirements, including tracking of relevant biomarkers. | We are seeking TA1 performer(s) that can fulfill the PROSPR requirements, including providing us with an in-home device to track C-reactive protein and perhaps other biomarkers of systemic inflammation. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| David Zakariaie | Senseye | david@senseye.co | Austin, TX | Senseye is pioneering the development of the first diagnostics for mental health by leveraging cutting-edge computer vision and neuroscience. Our technology captures high-resolution video of the eye and translates it into precise, tabular data that reflects underlying brain activity. This data-driven approach aims to provide objective, quantitative assessments for mental health conditions such as depression, anxiety, PTSD, and beyond. | We seek partners with complementary expertise in clinical trials, data science, machine learning, and behavioral health research to advance the development and validation of our diagnostic technology. Additionally, we are interested in collaborators who can provide access to diverse patient populations or specialized technical capabilities. | TA3: Second generation interventions |
| Vadim Gladyshev | Harvard Medical School | vgladyshev@rics.bwh.harvard.edu | Boston, MA | We focus on aging and longevity, develop biomarkers and discover and test longevity interventions | Complementary expertise | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Paul Dalhaimer | University of Tennessee | pdalhaim@utk.edu | Knoxville, TN | We use FDA-approved lipid nanoparticles to deliver mRNA to macrophages. The mRNA increases the fitness of the macrophages. Our technology improves the quality of life in those that are aged and/or immunocompromised. | We are looking for partners that are interested in rejuvenating the immune system and tissue repair capabilities of the aged. | TA3: Second generation interventions |
| Hamid Najafi | Hamid Najafi | hamid.najafi1330@gmail.com | San Francisco, CA | We develop a platforms for musicians from around the world perform live online easily and profitably for the music lovers from around the globe. We use AI to make this less costly for the musicians and more interesting for the viewers. | We would need full stack software developers, seniors who would be actual users of the platform, as well as UI/UX experts | TA1: PROSPR intrinsic capacity score |
| John Sedivy | Brown University | john_sedivy@brown.edu | Providence, RI | Brown University Center on the Biology of Aging focuses on molecular mechanisms of aging using a variety of model systems. We have programs in the areas of cellular senescence, epigenetics, chromatin architecture, rejuvenation, metabolism, and microbiome. Of particular relevance to this call is our program on the activation of retrotransposable elements as a novel molecular mechanism of aging. | Clinical partners for conducting clinical trials, in particular, the repurposing of FDA approved reverse transcriptase inhibitor drugs. | TA2: Repurposing FDA-approved interventions for healthspan extension, TA3: Second generation interventions |
| Albert Higgins-Chen | Yale University | a.higginschen@yale.edu | New Haven, CT | We develop aging biomarkers tailored for clinical trials. We constructed the TranslAGE knowledgebase, which utilizes harmonized datasets and pipelines to systematically report properties of any given aging biomarker including prediction of aging outcomes, confounders, test-retest reliability, relationship to mental health, and responsiveness to 51+ interventions. Interventions include diet, exercise, supplements, senolytics, rapamycin, metformin, hyperbaric oxygen, semaglutide, gene therapy. | We seek partners who wish to leverage the TranslAGE knowledgebase to inform clinical trial design (select biomarkers responsive to their intervention, conduct power analyses, identify confounders, find existing validation datasets). The available interventions are appropriate for all tracks (TA1, TA2, TA3). TranslAGE is currently focused on DNAm data due to availability of intervention data, but we would work with other teams to construct TranslAGE knowledgebases for other biomarker types. | TA1: PROSPR intrinsic capacity score, TA3: Second generation interventions |
| Albert-Laszlo Barabasi | Northeastern U & Harvard Medical | barabasi@gmail.com | Boston, MA | Network medicine and AI-based toolset to predict drug reproposing opportunities experimentally validated on 6000 FDA approved drugs). Identify the impact on specific aging hallmark and aging phenotype of each drug. Identify biochemical changes shared between multiple health improving drugs using omics data from blood and other expression data. Identify biochemical markers as surrogate endpoints. | We are looking for partners with experimental/patient/data capability in both animal models and humans, as well as any other tasks needed for TA2. Our expertise is in data analysis and prediction of drug efficacy for specific aging phenotypes. | TA3, TA3: Second generation interventions, TA1: PROSPR intrinsic capacity score |
| Eugenia Clerico | Northwestern University | eugenia.clerico@northwestern.edu | Evanston, IL | The Proteostasis Consortium is an established group of researchers studying protein homeostasis. Cellular proteostasis relies on a highly conserved set of biological pathways, known as "proteostasis network" (PN) which regulates protein synthesis, folding, assembly, localization, and degradation. Aging causes a decline in PN function, leading to diseases. We aim to understand PN decline to predict healthy aging, disease risk, and develop strategies to restore the PN to its youthful function. | We are seeking partners with expertise in conducting pre clinical trials. | TA1: PROSPR intrinsic capacity score, TA2: Repurposing FDA-approved interventions for healthspan extension, TA3: Second generation interventions |
| Samuel Dickson | Pentara Corporation | sdickson@pentara.com | Salt Lake City, UT | Pentara focuses on providing world-class statistical guidance and support focused on neurodegenerative and other progressive diseases, using traditional approaches when appropriate but deviating when traditional approaches fail to address relevant questions. As the primary users of data, we have also developed top-tier data management services that eliminate potentially study-killing issues often ignored by others. We use innovation and automation to help bring effective treatments to patients. | We care deeply about the patients that suffer from the many diseases we have helped develop treatments for and would love to have greater opportunities to use our knowledge and experience to improve people’s lives more directly by developing infrastructure to make it easier for an aging population to receive treatment and make lifestyle changes that will extend high-quality life. We seek partners that could help make this possible. | TA1: PROSPR intrinsic capacity score |
| Muhammad Mujeeb-U-Rahman | Integrated Medical Sensors Inc. | mujeeb@integratedmedicalsensors.com | Irvine, CA | We are a biosensor company with a multi-analyte, multi-modal sensing platform. | We are looking to partner with companies with expertise in clinical and regulatory aspects of resilience. | TA3: Second generation interventions |
| Alexey Strygin | Longevity Economics Institute | alexey.strygin@gmail.com | Digital nomad | 1) Longevity Economics Institute is focused on putting numbers on the longevity industry to convince governments and decision makers to channel more funding to the cause 2) Viva City is focused on creating a special regulatory zone to accelerate innovation in longevity biotech. | 1) Help anyone with economic projections, justifications, numbers, pharmacoeconomics etc 2) We want to hear everything you believe is wrong (or could be improved) with clinical trials. We have a once-in-a-lifetime opportunity to recreate the drug approval process from first principles in a special jurisdiction. | TA1: PROSPR intrinsic capacity score |
| Jiho Shin | Texas A&M University | jihoshin@tamu.edu | College Station, TX | Implantable and wearable medical devices or neural interfaces based on inorganic single-crystalline semiconductor nanomembrane devices obtained through layer transfer techniques. We can build, for example, sensors for pressure, temperature, ion concentrations, as well as LEDs, photodetectors, etc., all of which have 100-1000 nm thickness and made of materials conventional semiconductor materials such as Si, GaN, GaAs, etc. | We're open to all collaborations/partners. | TA3: Second generation interventions |
| Nik Papaioannou | Omma Therapeutics | NikP@ommatherapeutics.com | Newton, MA | Omma is developing oral plasma kallikrein (PKa) inhibitors for ocular and age-related diseases, where our initial focus is diabetic macular edema. Excessive activation of the plasma kallikrein kinin system (KKS) occurs during aging due to various pathological triggers (e.g. apoptotic cells, misfolded proteins, microplastics, others) to induce inflammation, thrombosis, vascular permeability and pain. In addition, our assays of KKS activation could be leveraged as healthspan biomarkers (TA1). | Our organization is looking for partners with expertise in clinical development, regulatory and biomarkers. | TA3: Second generation interventions |
| Tim Mullen | Intheon | sean.mullen@intheon.io | San Diego, CA | We have built the most expansive modular platform for state-of-the-art multi-modal neural and bio signal processing and end-to-end analytics, ML/DL classification and statistical modeling. We have performed on many gov-funded studies for multi-modal biomarker discovery, large-scale bio data, deployable multi-modal data capture and automated analytics; our team members developed the industry standard for multi-modal signal synchronization (Lab Streaming Layer) and widely used open source tools | Partners for clinical trials, data collection from target cohort(s), specific expertise in aging research. | TA3: Second generation interventions |
| Riley Sheehan | CFD Research | riley.sheehan@cfd-research.com | Huntsville, AL | The team at CFD Research has expertise in biomarker and multi-omic sensing, AI and data analysis, biomechanics and wearable sensor integration, modeling and simulation, and mobile and cloud app development. | We are looking for partners with experience in FDA/Regulatory/Insurance, Decentralized clinical trials, and Commercialization | TA1: PROSPR intrinsic capacity score |
| Ravi Solanki | CFDX | ravi@cfdx.io | San Francisco and London, PA | Building multi-omic multi-modal transformer models that ingest and infer upon longitudinal studies of aging and disease, for neurodegeneration diagnostics and mechanism discovery. | Sample processing and data generation partners, clinical partners for cohort studies. | TA3: Second generation interventions |
| Eric Van Gieson | EPOCH Epigenetics | Evangieson@epochepigenetics.com | Baltimore, MD, MD | Our organization is focused on measuring and modulating host response, with a priority on inflammation. We use epigenetic tools developed under the DARPA ECHO program to measure the epigenetic response to disease and environmental exposures. Separately, we are teamed with ReAlta Life Sciences which has a drug in phase 2 clinical trials showing the ability to modulate C1 complement response and netosis in the context of sepsis, COPD, cancer, and neurological disorders. | We are looking for partners with access to advanced computational tools for handling multiomic data as well as access to logitudinal clinical samples and ongoing clincal studies (including KARDIA or similar) for us to prospectively evaluate the impacts of our therapeutic platform and epigenetic host response testing. | TA1: PROSPR intrinsic capacity score |
| Alan Fine | Alentic Microscience Inc. | afine@alentic.com | Halifax, Nova Scotia, Canada | Rapid, highly portable, easy to use, economical, multifunctional in vitro diagnostic technology | Identification of relevant biomarkers, productization of assays | TA1: PROSPR intrinsic capacity score |
| ashish rajput | Infinity biosciences GmbH | ashish.medbt@gmail.com | Stuttgart, Germany | We are using single cell RNA seq and multi omics data analysis to find novel molecular targets for stem cell aging and age related diseases. | We are looking for scientific collaborators as well as investors to pursue this project. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Michelle Farrington | AFFOA | mfarrington@affoa.org | Cambridge, MA | AFFOA provides capabilities in e-textile and wearable design and manufacturing. This can help enable distributed sensing and actuation for your wearable platforms. AFFOA offers prototyping services along to the research community to realize next generation textile-based soft systems. | Researchers looking to further prototypes to ready for in-animal and human study. | TA3: Second generation interventions |
| Julia Komissarchik | Glendor, Inc | julia@glendor.com | Draper, UT | Software for PHI Deidentification of Multimodal Medical Data to empower medical data sharing, while protecting patient's privacy. Fully automatic: no tweaking or customization needed At Source (on prem or cloud): unlike APIs and 3rd party services that require sensitive data to be shared Easy to integrate and use: no BAA required, 1 min to install and start running Multiple Modalities Multiple Formats: medical images, reports, videos, photos, audio | We are looking for partners who would like to deidentify data contributed by the patients. Use Case 1: deidentification of data by the patients and their caretakers, to ensure that the patients are comfortable sharing the data. Use Case 2: deidentification of data before it enters the aggregator site, to ensure that the patients are comfortable sharing the data & to avoid HIPAA violations and reputation damage to the institutions. Can be used as a standalone tool or to augment existing workflow. | TA3: Second generation interventions |
| Deependra Thapa | School of Public Health- Bloomington, Indiana University | dethapa@iu.edu | Bloomington, IN | Our department focuses on developing rigorous statistical methods for aging research, particularly testing the compression of morbidity (CoM) hypothesis. CoM explores the balance between healthy lifespan and morbidity as longevity increases. Our project assesses whether life-extending interventions compress morbidity by comparing rates of decline in vitality and survival using intraindividual vitality and population survival curves, advancing insights into how aging interventions affect health. | Our organization seeks teaming partners with expertise in aging research, biostatistics, and innovative interventions targeting healthspan. Ideal collaborators include those skilled in analyzing vitality and survival data, developing biomarkers, and conducting translational studies in human and animal models. We value partners committed to advancing rigorous methods to test the compression of morbidity hypothesis and fostering interdisciplinary approaches to promote healthy aging. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Paola Sebastiani | Tufts Medical Center | psebastiani@tuftsmedicalcenter.org | Boston, MA | Disease is considered an inevitable effect of aging but our studies of centenarians have shown that some people can reach extreme old ages in good health and good cognitive and physical functions. I work with cohorts of centenarians to discover genetic and non genetic factors that promote resilience and resistance to disease and aging-related functional declines. | My work uses advanced statistical modeling techniques. It would be useful to team up with experts in AI | TA3: Second generation interventions |
| Aaron King | Aeon Biomarkers | aaron.k.biology@gmail.com | Austin, TX | We are collecting biomarker information to clearly define the problem of aging by cataloging which biomarkers change with age and which ones currently already have solutions. | We need more sources of large-scale data. | TA3: Second generation interventions |
| Weiwei Dang | Baylor College of Medicine | weiwei.dang@bcm.edu | Houston, TX | Clinical and biomarker studies on the effects of dry fasting (Ramadan fasting) in patients with metabolic syndromes | Clinical partners from other cities; pharmaceutical partners with drugs that could mimic dry fasting (Ramadan fasting) effects | TA1: PROSPR intrinsic capacity score |
| Cong Trinh | University of Tennessee Knoxville | ctrinh@utk.edu | Knoxville, TN | Cellular metabolism, omics integration, AI/ML, cellular robustness, and stress responses. | Partners with clinical expertise, physiological and biochemical data/samples, and complementary expertise. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Abhishek Singh | MIT | abhi24@media.mit.edu | Boston, MA | Our team at MIT has a strong background in applying/designing machine learning algorithms. We build systems and algorithms for siloed and fragmented data. Recent projects include harmonization of distributed datasets, with a focus on longitudinal data analysis, bioinformatics, and dynamic treatment optimization. Our work in decentralized AI will be relevant for decentralized trials, privacy-preserving data analysis, and drug repurposing models. | We are looking to team up with experts in systems bio, clinical trials, hardware, and testing companies. | TA2: Repurposing FDA-approved interventions for healthspan extension |
| Catherine Bentley | linedanceAI | cbentley@linedanceAI.com | Dallas, TX | linedanceAI is the world's first human movement generative AI prompted only by de-identified patient videos to quantify pain and dysfunction. Our flagship software Movality® helps musculoskeletal providers personalize care, monitor progress to patient goals and generate reports that support clinical reasoning progress. Our Movement Quality Index score may be considered the physiological dysfunction component in the PROSPR Intrinsic Capacity Score. | Orthopedic specialists, geriatric healthcare providers or researchers, biomechanical specialists in wellness and aging, data scientists, | TA1: PROSPR intrinsic capacity score, TA3: Second generation interventions |
| Valentin Normand | Ambr Institute | valentin@ambr.no | Minneapolis, MN | The Ambr Institute researches and develops AI algorithms for personalized prevention and diagnostic of age associated conditions and rare disease. We have a focus on metabolic conditions and dementia. Ambr developed a medical device software to facilitate early detection and personalized prevention in primary care settings, targeted toward physician's usage, to promote healthy ageing at scale. | We are looking for new collaborators and funding partners. The priority is to identify parties that are interested in piloting the solution (clinics, hospitals, ambulatory), and testing it within their medical speciality. | TA1: PROSPR intrinsic capacity score |
| Amberlie Clutterbuck | The Emmes Company | aclutterbuck@emmes.com | Rockville, MD | Emmes is a full-service clinical research organization serving government, biopharmaceutical, non-profit, & academic partners in achieving their development & human health goals. Our industry leading capabilities in Vaccines & Infectious Diseases, Neuroscience, Ophthalmology, Cell & Gene Therapy & Rare Diseases in the following areas: Statistical & Data Coordinating Centers, Clinical Research Support Services Partnerships, Full Service Clinical Trials, & Clinical Site Monitoring Centers. | Emmes is seeking to work with partners on in providing decentralized clinical trials and clinical trial protocols. | TA1: PROSPR intrinsic capacity score |
| Daohong Zhou | University of Texas Health San Antonio | zhoud@uthscsa.edu | San Antonio, TX | Senolytic drug discovery and development for aging and age-related diseases; using proteolysis targeting chimera (PROTAC) technology to develop safer and more effective anti-aging therapeutics; preclinical development of novel anti-aging therapeutics; | CRO to conduct IND enabling studies and apply for IND approval | TA3: Second generation interventions |